DUPLIVIR® (tenofovir disoproxil fumarate + lamivudine)

  • ACTIVE INGREDIENT: tenofovir disoproxil fumarate + lamivudine
  • CONCENTRATION: 300mg per each
  • PRESENTATION: 30 coated tablets


DUPLIVIR® belongs to a group of antiviral drugs, also known as antiretrovirals, and is indicated for the treatment of HIV-1 infection.


DUPLIVIR® is contraindicated in patients with previously demonstrated hypersensitivity to any of the product’s components.

As this is a tablet containing the combination of lamivudine and tenofovir disoproxil fumarate, DUPLIVIR® should not be co-administered with other drugs containing lamivudine or tenofovir disoproxil fumarate. Due to the similarities between emtricitabine and lamivudine, DUPLIVIR® should also not be co-administered with products containing emtricitabine. There is interaction between zalcitabine and laminudin, therefore coadministration of zalcitabine and DUPLIVIR® is not recommended.

DUPLIVIR® should not be coadministered concomitantly with drugs based on adenofovir dipivoxil.

It is not recommended to use DUPLIVIR® as a component of a three-nucleoside administration program.

Patients with renal insufficiency should not use DUPLIVIR®, because dose adjustment is not possible.

There are no age-related contraindications; however, safety and efficacy in pediatric patients under 18 years of age have not been established.


Rua Joaquim Faustino de Camargo, 201, Jardim São Paulo, Taboão da Serra - SP (11) 4138-8200 • © Blanver 2020, Todos os direitos reservados